We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+10.86%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$5.06B
AUM Growth
–
Cap. Flow
+$4.02B
Cap. Flow %
79.47%
Top 10 Hldgs %
79.91%
Holding
75
New
67
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$880M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$674M
3
GHDX
Genomic Health, Inc.
GHDX
+$448M
4
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$420M
5
INCY icon
Incyte
INCY
+$324M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 48.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$856M 16.93%
+10,771,138
New +$880M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$608M 12.02%
+19,322,947
New +$674M
GHDX
3
DELISTED
Genomic Health, Inc.
GHDX
$433M 8.56%
+13,650,835
New +$448M
GEVA
4
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$387M 7.66%
+9,223,182
New +$420M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$5.08B
$362M 7.16%
+19,955,126
New +$275M
INCY icon
6
Incyte
INCY
$25.9B
$326M 6.44%
+14,810,559
New +$324M
VPHM
7
DELISTED
VIROPHARMA INC
VPHM
$244M 4.83%
+8,528,603
New +$225M
XOMA
8
DELISTED
Xoma
XOMA
$73.6M 1.46%
+1,013,729
New +$75.5M
GILD icon
9
Gilead Sciences
GILD
$181B
$63.9M 1.26%
+1,245,800
New +$64.9M
AEGR
10
DELISTED
Aegerion Pharmaceuticals
AEGR
$58.5M 1.16%
+924,343
New +$49.1M
HALO icon
11
Halozyme
HALO
$12.3B
$52.1M 1.03%
+6,553,150
New +$41.7M
RPRX
12
DELISTED
Repros Therapeutics Inc.
RPRX
$51.3M 1.01%
+2,778,654
New +$49.1M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$12.9B
$43.7M 0.86%
+783,311
New +$48.8M
CERS icon
14
Cerus
CERS
$566M
$37.4M 0.74%
+8,455,306
New +$40.9M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$35.2M 0.7%
+525,113
New +$23.6M
VNDA icon
16
Vanda Pharmaceuticals
VNDA
$319M
$32M 0.63%
+3,966,179
New +$26.7M
ARIA
17
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$25.4M 0.5%
+1,450,000
New +$25.7M
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
$21.5M 0.42%
+900,000
New +$14.3M
ICPT
19
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$20.8M 0.41%
+462,847
New +$15.8M
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
$19.6M 0.39%
+796,662
New +$20M
PGNX
21
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$18.7M 0.37%
+4,200,000
New +$18.8M
DSCI
22
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$18.1M 0.36%
+1,358,857
New +$17.5M
AVNR
23
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$16.5M 0.33%
+3,578,591
New +$12.3M
INFI
24
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$16.5M 0.33%
+1,016,433
New +$31.5M
QCOR
25
DELISTED
QUESTCOR PHARMA INC
QCOR
$14.4M 0.28%
+315,846
New +$11.2M
1
2 3

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Julian Baker, which disclosed 75 positions worth $5.06B. Its ten largest holdings account for 80% of the portfolio.

Its largest position is PHARMACYCLICS INC: 10,771,138 shares worth $856M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets.

  • Julian Baker's largest Q2 2013 buy was PHARMACYCLICS INC: 10,771,138 shares worth $856M.
  • Julian Baker's ten largest holdings make up 80% of its $5.06B portfolio in Q2 2013.
  • Julian Baker disclosed 75 positions in Q2 2013, its first 13F filing on record.

Based on Baker Bros. Advisors's 13F filing for Q2 2013, filed 14 Aug 2013.